Efficacy and Safety of BG2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids.
Status:
Recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to demonstrate the superior efficacy versus placebo of
BG2109 alone and in combination with add-back therapy for the reduction of heavy menstrual
bleeding associated with uterine fibroids in premenopausal women.